Filter News

Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients

Published: May 19, 2016

THOUSAND OAKS, Calif., May 18, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data from across the oncology portfolio, including Kyprolis® (carfilzomib), IMLYGIC® (talimogene laherparepvec), Vectibix® (panitumumab) and Neulasta® (pegfilgrastim) will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2016.

"As a leader in patient-focused oncology research, Amgen is committed to translating innovative science into treatments that make a difference in the lives of people suffering from cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The breadth and depth of data we're presenting at ASCO demonstrates our commitment to finding solutions to some of the toughest cancers. We are thankful for our research partners who help us achieve this mission, and we look forward to sharing these results at ASCO."

Amongst the Kyprolis abstracts to be presented at the meeting will be a new subgroup analysis from the Phase 3 ASPIRE trial which compared Kyprolis in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed multiple myeloma patients who had early disease progression following prior therapy (including transplant).

Presentations highlighting Kyprolis data include:

  • Carfilzomib, Lenalidomide, and Dexamethasone (KRd) vs. Lenalidomide and Dexamethasone (Rd) in Patients with Relapsed Multiple Myeloma (RMM) and Early Progression During Prior Therapy: Secondary Analysis From the Phase 3 Study ASPIRE (NCT01080391)
    Abstract #8045, Poster, Monday, June 6 at 8 a.m. CDT in McCormick Place, Hall A
  • Risk of Hypertension (HTN) and Malignant Hypertension (mHTN) in Patients Treated for Multiple Myeloma (MM)
    Abstract #8049, Poster, Monday, June 6 at 8 a.m. CDT in McCormick Place, Hall A
  • Transitions Across Different Lines of Therapy in the Medicare-Enrolled Patient Population with Multiple Myeloma
    Abstract #8043, Poster, Monday, June 6 at 8 a.m. CDT in McCormick Place, Hall A
  • Treatment Regimens and Duration of Lines of Therapy in Medicare-Enrolled Patients with Multiple Myeloma
    Abstract #8046, Poster, Monday, June 6 at 8 a.m. CDT in McCormick Place, Hall A
  • Costs Associated With Treatment Induced Peripheral Neuropathy in Patients with Multiple Myeloma (MM)
    Abstract #8048, Poster, Monday, June 6 at 8 a.m. CDT in McCormick Place, Hall A
  • Healthcare Costs Among Multiple Myeloma (MM) Patients (Pts) without Stem Cell Transplant (SCT)
    Abstract #8059, Poster, Monday, June 6 at 8 a.m. CDT in McCormick Place, Hall A
  • Retrospective Study of Frequency and Cost of Multiple Myeloma (MM) Complications and Treatment (Tx) Related Adverse Events (AEs)
    Abstract #8060, Poster, Monday, June 6 at 8 a.m. CDT in McCormick Place, Hall A
  • Economic Evaluation of Carfilzomib + Lenalidomide + Dexamethasone (KRd) vs. Lenalidomide + Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (R/RMM)
    Abstract #8021, Poster Discussion, Monday, June 6 at 3 p.m. CDT in McCormick Place, E354b

Two abstracts on the MASTERKEY-265 trial of IMLYGIC in combination with pembrolizumab in patients with unresectable Stage IIIB-IV melanoma will be presented:

  • Efficacy Analysis of MASTERKEY-265 Phase 1b Study of Talimogene Laherparepvec (T-VEC) and Pembrolizumab (Pembro) for Unresectable Stage IIIBIV Melanoma
    Abstract #9568, Poster Presentation, Saturday, June 4 from 1-4:30 p.m. CDT in McCormick Place, Hall A
  • A Phase 1/3, Multicenter Trial of Talimogene Laherparepvec in Combination with Pembrolizumab for Unresected, Stage IIIB-IV Melanoma (MASTERKEY-265)
    Abstract #TPS9598, Poster Presentation, Saturday, June 4 from 1-4:30 p.m. CDT in McCormick Place, Hall A

Key data from two abstracts and one publication will be presented on Vectibix, including the final results from a Phase 3 trial of Vectibix and best supportive care (BSC) versus BSC in chemorefractory wild-type KRAS exon 2 and wild-type RAS metastatic colorectal cancer (mCRC):

  • Association of ECOG Performance Status with Efficacy in Patients Receiving Panitumumab with Best Supportive Care (BSC) vs. BSC Alone for Chemorefractory Metastatic Colorectal Cancer
    Publication only
  • Final Results from a Phase 3 Trial Evaluating Panitumumab (pmab) + Best Supportive Care (BSC) vs. BSC in Chemorefractory Wild-type (WT) KRAS Exon 2 and WT RAS Metastatic Colorectal Cancer (mCRC)
    Abstract #3536, Poster, Saturday, June 4 at 8 a.m. CDT in McCormick Place, Hall A
  • Efficacy of Panitumumab  vs. Cetuximab  in Patients with Wild-type  KRAS Exon 2 Metastatic Colorectal Cancer Treated with Prior Bevacizumab: Results from ASPECCT
    Abstract #3538, Poster, Saturday, June 4 at 8 a.m. CDT in McCormick Place, Hall A

Three abstracts will be presented on Neulasta and NEUPOGEN® (filgrastim), providing new insights into their role in supportive care, including:

  • NOLAN: A Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Naproxen (N) or Loratadine (L) vs. No Intervention on Bone Pain in 600 Patients (pts) with Early-Stage Breast Cancer Receiving Chemotherapy (chemo) and Pegfilgrastim (PEG)
    Abstract #10021, Poster Discussion, Monday, June 6 at 4:45 p.m. CDT in McCormick Place, S102
  • Burden of Febrile Neutropenia Hospitalizations (FNH) in U.S. Clinical Practice, by Use and Patterns of Colony-Stimulating Factor Prophylaxis (CP)
    Abstract #6568, Poster, Saturday, June 4 at 1 p.m. CDT in McCormick Place, Hall A
  • Risk Factors for Febrile Neutropenia in Cancer Patients Treated With Chemotherapy
    Abstract #6559, Poster, Saturday, June 4 at 1 p.m. CDT in McCormick Place, Hall A

One abstract will be presented on investigational agent ABP 215, which is being developed as a biosimilar to bevacizumab:

  • Randomized, Double-Blind, Phase 3 Study Evaluating Efficacy and Safety of ABP 215 Compared with Bevacizumab in Patients with Non-Squamous NSCLC
    Abstract #9095, Poster Presentation, Saturday, June 4, at 8 a.m. CDT in McCormick Place, Hall A

Abstracts are currently available on the ASCO website.

About Kyprolis® (carfilzomib) 
Proteasomes play an important role in cell function and growth by breaking down proteins that are damaged or no longer needed.1 Kyprolis has been shown to block proteasomes, leading to an excessive build-up of proteins within cells.2 In some cells, Kyprolis can cause cell death, especially in myeloma cells because they are more likely to contain a higher amount of abnormal proteins.2 The irreversibility of Kyprolis' binding has also been shown to offer a more sustained inhibition of the targeted enzymes.3

Kyprolis is approved in the U.S. for the following:

  • In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Kyprolis is also approved in Argentina, Israel, Kuwait, Mexico, Thailand, Colombia, Korea, Canada and the European Union. Additional regulatory applications for Kyprolis are underway and have been submitted to health authorities worldwide.

Kyprolis is a product of Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals is a subsidiary of Amgen and holds development and commercialization rights to Kyprolis globally, excluding Japan.

For more information, please visit www.kyprolis.com.

Important Safety Information Regarding Kyprolis® (carfilzomib) for Injection

INDICATION(S)

  • KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • KYPROLIS® (carfilzomib) is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

IMPORTANT SAFETY INFORMATION

Cardiac Toxicities

  • New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of KYPROLIS. Some events occurred in patients with normal baseline ventricular function. Death due to cardiac arrest has occurred within one day of KYPROLIS administration.
  • Monitor patients for clinical signs or symptoms of cardiac failure or cardiac ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold KYPROLIS for Grade 3 or 4 cardiac adverse events until recovery, and consider whether to restart KYPROLIS at 1 dose level reduction based on a benefit/risk assessment.
  • While adequate hydration is required prior to each dose in Cycle 1, monitor all patients for evidence of volume overload, especially patients at risk for cardiac failure. Adjust total fluid intake as clinically appropriate in patients with baseline cardiac failure or who are at risk for cardiac failure.
  • In Patients > 75 years, the risk of cardiac failure is increased. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or arrhythmias may be at greater risk for cardiac complications and should have a comprehensive medical assessment (including blood pressure and fluid management) prior to starting treatment with KYPROLIS and remain under close follow-up.

Acute Renal Failure

  • Cases of acute renal failure and renal insufficiency adverse events (including renal failure) have occurred in patients receiving KYPROLIS. Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received KYPROLIS monotherapy. Monitor renal function with regular measurement of the serum creatinine and/or estimated creatinine clearance. Reduce or withhold dose as appropriate.

Tumor Lysis Syndrome

  • Cases of Tumor Lysis Syndrome (TLS), including fatal outcomes, have occurred in patients receiving KYPROLIS. Patients with multiple myeloma and a high tumor burden should be considered at greater risk for TLS. Adequate hydration is required prior to each dose in Cycle 1, and in subsequent cycles as needed. Consider uric acid lowering drugs in patients at risk for TLS. Monitor for evidence of TLS during treatment and manage promptly. Withhold KYPROLIS until TLS is resolved.

Pulmonary Toxicity

  • Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in patients receiving KYPROLIS. Some events have been fatal. In the event of drug-induced pulmonary toxicity, discontinue KYPROLIS.

Pulmonary Hypertension

  • Pulmonary arterial hypertension (PAH) was reported in patients treated with KYPROLIS. Evaluate with cardiac imaging and/or other tests as indicated. Withhold KYPROLIS for PAH until resolved or returned to baseline and consider whether to restart KYPROLIS based on a benefit/risk assessment.

Dyspnea

  • Dyspnea was reported in patients treated with KYPROLIS. Evaluate dyspnea to exclude cardiopulmonary conditions including cardiac failure and pulmonary syndromes. Stop KYPROLIS for Grade 3 or 4 dyspnea until resolved or returned to baseline. Consider whether to restart KYPROLIS based on a benefit/risk assessment.

Hypertension

  • Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with KYPROLIS. Some of these events have been fatal. Monitor blood pressure regularly in all patients. If hypertension cannot be adequately controlled, withhold KYPROLIS and evaluate. Consider whether to restart KYPROLIS based on a benefit/risk assessment.

Venous Thrombosis

  • Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with KYPROLIS. Thromboprophylaxis is recommended for patients being treated with the combination of KYPROLIS with dexamethasone or with lenalidomide plus dexamethasone. The thromboprophylaxis regimen should be based on an assessment of the patient's underlying risks.
  • Patients using oral contraceptives or a hormonal method of contraception associated with a risk of thrombosis should consider an alternative method of effective contraception during treatment with KYPROLIS in combination with dexamethasone or lenalidomide plus dexamethasone.

Infusion Reactions

  • Infusion reactions, including life-threatening reactions, have occurred in patients receiving KYPROLIS. Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina. These reactions can occur immediately following or up to 24 hours after administration of KYPROLIS. Premedicate with dexamethasone to reduce the incidence and severity of infusion reactions. Inform patients of the risk and of symptoms of an infusion reaction and to contact a physician immediately if they occur.

Thrombocytopenia

  • KYPROLIS causes thrombocytopenia with recovery to baseline platelet count usually by the start of the next cycle. Thrombocytopenia was reported in patients receiving KYPROLIS. Monitor platelet counts frequently during treatment with KYPROLIS. Reduce or withhold dose as appropriate.

Hepatic Toxicity and Hepatic Failure

  • Cases of hepatic failure, including fatal cases, have been reported during treatment with KYPROLIS. KYPROLIS can cause increased serum transaminases. Monitor liver enzymes regularly regardless of baseline values. Reduce or withhold dose as appropriate.

Thrombotic Microangiopathy

  • Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal outcome have occurred in patients receiving KYPROLIS. Monitor for signs and symptoms of TTP/HUS. Discontinue KYPROLIS if diagnosis is suspected. If the diagnosis of TTP/HUS is excluded, KYPROLIS may be restarted. The safety of reinitiating KYPROLIS therapy in patients previously experiencing TTP/HUS is not known.

Posterior Reversible Encephalopathy Syndrome (PRES)

  • Cases of PRES have occurred in patients receiving KYPROLIS. PRES was formerly known as Reversible Posterior Leukoencephalopathy Syndrome. Consider a neuroradiological imaging (MRI) for onset of visual or neurological symptoms. Discontinue KYPROLIS if PRES is suspected and evaluate. The safety of reinitiating KYPROLIS therapy in patients previously experiencing PRES is not known.

Embryo-fetal Toxicity

  • KYPROLIS can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals.
  • Females of reproductive potential should be advised to avoid becoming pregnant while being treated with KYPROLIS. Males of reproductive potential should be advised to avoid fathering a child while being treated with KYPROLIS. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the patient should be apprised of the potential hazard to the fetus.

ADVERSE REACTIONS

  • The most common adverse events occurring in at least 20% of patients treated with KYPROLIS in the combination therapy trials: anemia, neutropenia, diarrhea, dyspnea, fatigue, thrombocytopenia, pyrexia, insomnia, muscle spasm, cough, upper respiratory tract infection, hypokalemia.
  • The most common adverse events occurring in at least 20% of patients treated with KYPROLIS in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral.

Please see full Prescribing Information at www.kyprolis.com.

About IMLYGIC (talimogene laherparepvec)
IMLYGIC is a genetically modified herpes simplex type 1 virus that is injected directly into tumors. IMLYGIC replicates inside tumor cells and produces GM-CSF, an immunostimulatory protein. IMLYGIC then causes the cell to rupture and die in a process called lysis. The rupture of the cancer cells causes the release of tumor-derived antigens, which together with virally derived GM-CSF may help to promote an anti-tumor immune response. However, the exact mechanism of action is unknown.

IMLYGIC is the first oncolytic viral therapy approved by the U.S. Food and Drug Administration  (FDA) based on therapeutic benefit demonstrated in a pivotal study. IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.

Important Safety Information

Contraindications

  • Do not administer IMLYGIC to immunocompromised patients, including those with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy, due to the risk of life-threatening disseminated herpetic infection.
  • Do not administer IMLYGIC to pregnant patients.

Warnings and Precautions

  • Accidental exposure to IMLYGIC may lead to transmission of IMLYGIC and herpetic infection, including during preparation and administration. Health care providers, close contacts, pregnant women, and newborns should avoid direct contact with injected lesions, dressings, or body fluids of treated patients. The affected area in exposed individuals should be cleaned thoroughly with soap and water and/or a disinfectant.
  • Caregivers should wear protective gloves when assisting patients in applying or changing occlusive dressings and observe safety precautions for disposal of used dressings, gloves, and cleaning materials. Exposed individuals should clean the affected area thoroughly with soap and water and/or a disinfectant.
  • To prevent possible inadvertent transfer of IMLYGIC to other areas of the body, patients should be advised to avoid touching or scratching injection sites or occlusive dressings.
  • Herpetic infections: Herpetic infections (including cold sores and herpetic keratitis) have been reported in IMLYGIC-treated patients. Disseminated herpetic infection may also occur in immunocompromised patients. Patients who develop suspicious herpes-like lesions should follow standard hygienic practices to prevent viral transmission.
  • Patients or close contacts with suspected signs or symptoms of a herpetic infection should contact their health care provider to evaluate the lesions. Suspected herpetic lesions should be reported to Amgen at 1-855-IMLYGIC (1-855-465-9442). Patients or close contacts have the option of follow-up testing for further characterization of the infection.
  • IMLYGIC is sensitive to acyclovir. Acyclovir or other antiviral agents may interfere with the effectiveness of IMLYGIC. Consider the risks and benefits of IMLYGIC treatment before administering antiviral agents to manage herpetic infection.
  • Injection Site Complications: Necrosis or ulceration of tumor tissue may occur during IMLYGIC treatment. Cellulitis and systemic bacterial infection have been reported in clinical studies. Careful wound care and infection precautions are recommended, particularly if tissue necrosis results in open wounds.
  • Impaired healing at the injection site has been reported. IMLYGIC may increase the risk of impaired healing in patients with underlying risk factors (e.g., previous radiation at the injection site or lesions in poorly vascularized areas). If there is persistent infection or delayed healing of the injection site, consider the risks and benefits of continuing treatment.
  • Immune-Mediated events including glomerulonephritis, vasculitis, pneumonitis, worsening psoriasis, and vitiligo have been reported in patients treated with IMLYGIC. Consider the risks and benefits of IMLYGIC before initiating treatment in patients who have underlying autoimmune disease or before continuing treatment in patients who develop immune-mediated events.
  • Plasmacytoma at Injection Site: Plasmacytoma in proximity to the injection site has been reported in a patient with smoldering multiple myeloma after IMLYGIC administration in a clinical study. Consider the risks and benefits of IMLYGIC in patients with multiple myeloma or in whom plasmacytoma develops during treatment.

Adverse Reactions

  • The most commonly reported adverse drug reactions (>25%) in IMLYGIC-treated patients were fatigue, chills, pyrexia, nausea, influenza-like illness, and injection site pain. Pyrexia, chills, and influenza-like illness can occur at any time during IMLYGIC treatment, but were more frequent during the first 3 months of treatment.
  • The most common Grade 3 or higher adverse reaction was cellulitis.

Please see full Prescribing Information and Medication Guide for IMLYGIC at www.IMLYGIC.com.

About Vectibix® (panitumumab)
Vectibix is the first fully human monoclonal anti-epidermal growth factor receptor (EGFR) antibody approved by the  FDA for the treatment of metastatic colorectal cancer (mCRC). Vectibix was approved in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.

In May 2014, the FDA approved Vectibix for use in combination with FOLFOX, as first-line treatment in patients with wild-type KRAS (exon 2) mCRC. With this approval, Vectibix became the first-and-only biologic therapy indicated for use with FOLFOX, one of the most commonly used chemotherapy regimens, in the first-line treatment of mCRC for patients with wild-type KRAS mCRC.

Important U.S. Product Information
Vectibix® is indicated for the treatment of patients with wild-type KRAS (exon 2 in codons 12 or 13) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use:

  • As first-line therapy in combination with FOLFOX
  • As monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy

Limitation of Use: Vectibix® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

WARNING: DERMATOLOGIC TOXICITY 
Dermatologic Toxicity: Dermatologic toxicities occurred in 90 percent of patients and were severe (NCI-CTC grade 3 or higher) in 15% of patients receiving Vectibix monotherapy.

In Study 1, dermatologic toxicities occurred in 90% of patients and were severe (NCI-CTC grade 3 and higher) in 15% of patients with mCRC receiving Vectibix®.

To read full press release, please click here.

Back to news